Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant/Adjuvant Trial of Darovasertib in Ocular Melanoma
NCT05187884Phase 2Completed
- Sponsor
- St Vincent's Hospital
- Start
- May 2022
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of darovasertib in Uveal melanoma (UM), sponsored by St Vincent's Hospital. Primary endpoints: Adverse Events assessed by CTCAE v5.0 at 56 days and Percentage of participants that complete the 56-day treatment period. Started May 2022; status: completed.
02
Drugs
darovasertib
03
Conditions
Uveal melanoma (UM)
Beyond the preview
Go deeper on NCT05187884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05187884.